Letters, Testimony & Comments

RE: SEC Release No. 34-60611 Dear Deputy Secretary Harmon: On behalf of its members, the Biotechnology Industry Organization (“...
September 29 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 20 2009
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO...
October 27 2008
Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments...
October 27 2008
Dear Chairman Cox and Director Thomsen: On behalf of its members, the Biotechnology Industry Organization (“BIO”) would...
September 22 2008
Dear Chairman Schapiro: The Biotechnology Industry Organization (BIO) thanks the Securities and Exchange Commission (SEC or Commission)...
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
September 29 2009
BIO supports NASDAQ’s proposal to temporarily suspend delisting standards during the economic crisis
April 20 2009
The Biotechnology Industry Organization (BIO) is pleased to have the opportunity to comment on the Securities and Exchange Commission’s (SEC or Commission) proposed roadmap to implement a global set of financial accounting standards.
October 27 2008
On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and Exchange Commission (“SEC” or “Commission”) to address excessive market fluctuations of security prices exacerbated by market manipulation, including abusive naked short selling and false rumors. As a result of this market manipulation, the securities prices of many small biotechnology companies have been substantially driven down, harming overall investor confidence in biotechnology companies. Specifically, diminished investor confidence adversely impairs the liquidity and ultimately the viability of emerging biotechnology companies.
October 27 2008
BIO commends the SEC on implementation of the new 10b-21 naked short selling anti-fraud rule and the "Hard T+3 Close Out Requirement" proposal.
May 15 2013
H.R. 1952 will stimulate trading for small public companies.
July 20 2012
New bill will update SEC filing status classifications to ease costly regulatory burdens on small public companies 
June 29 2011
“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease and Save Lives” Provides Roadmap for Transformative Policy Changes
February 11 2011
BIO announces that President and CEO James C. Greenwood will ring the closing bell at The NASDAQ Stock Marke.